Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats

References

• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–54
   PubMed Web of Science ®Google Scholar
• Chang TKH, Weber GF, Crespi CL, et al. (1993). Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629–37
   PubMed Web of Science ®Google Scholar
• Denisov IG, Baas BJ, Grinkova YV, et al. (2007). Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. J Biol Chem 282:7066–76
   PubMed Web of Science ®Google Scholar
• Di Re J, Lee C, Riddick DS. (1999). Lack of mechanism-based inactivation of rat hepatic microsomal P450 by doxorubicin. Can J Physiol Pharmacol 77:589–97
   PubMed Web of Science ®Google Scholar
• Ghosal A, Satoh H, Thomas PE, et al. (1996). Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940–7
   PubMed Web of Science ®Google Scholar
• Goldstein I, Rivlin N, Shoshana OY, et al. (2013). Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis 34:190–8
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, et al. (1994). Regioselective biotransformation of midazolam by members of the human cytochrome P450 (CYP3A) subfamily. Biochem Pharmacol 47:1643–53
   PubMed Web of Science ®Google Scholar
• Gray JP, Mishin V, Heck DE, et al. (2010). Inhibition of NADPH cytochrome P450 reductase by the model sulfur mustard vesicant 2-chloroethyl ethyl sulfide is associated with increased production of reactive oxygen species. Toxicol Appl Pharmacol 247:76–82
   PubMed Web of Science ®Google Scholar
• Hoch M, Hoever P, Alessi F, et al. (2013). Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. Eur J Clin Pharmacol 69:523–32
   PubMed Web of Science ®Google Scholar
• Konishi H, Sudo M, Sumi M, et al. (2005). Pharmacokinetic behavior of micafungin in rats with carbon tetrachloride-induced acute hepatic failure. Biol Pharm Bull 28:556–9
   PubMed Web of Science ®Google Scholar
• Lee CM, Pohl J, Morgan ET. (2009). Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 37:865–72
   PubMed Web of Science ®Google Scholar
• Levin W, Lu AYH, Jacobson M, et al. (1973). Lipid peroxidation and the degradation of cytochrome P-450 heme. Arch Biochem Biophys 158:842–52
   PubMed Web of Science ®Google Scholar
• Li XY, Zhang C, Wang H, et al. (2008). Tumor necrosis factor α partially contributes to lipopolysaccharide-induced downregulation of CYP3A in fetal liver: its repression by a low dose LPS pretreatment. Toxicol Lett 179:71–7
   PubMed Web of Science ®Google Scholar
• Marchand DJ, Renton KW. (1981). Depression of cytochrome P-450-dependent drug biotransformation by adriamycin. Toxicol Appl Pharmacol 58:83–8
   PubMed Web of Science ®Google Scholar
• Mimnaugh EG, Trush MA, Ginsburg E, et al. (1981a). The effects of adriamycin in vitro and in vivo on hepatic microsomal drug-metabolizing enzymes: role of microsomal lipid peroxidation. Toxicol Appl Pharmacol 61:313–25
   PubMed Web of Science ®Google Scholar
• Mimnaugh EG, Trush MA, Gram TE. (1981b). Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation. Biochem Pharmacol 30:2797–804
   PubMed Web of Science ®Google Scholar
• Rastogi P, Anderson SJ, Bear HD, et al. (2008). Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–85
   PubMed Web of Science ®Google Scholar
• Sakr SA, Abo-EI-Yazid SM (2012). Effect of fenugreek seed extract on adriamycin-induced hepatotoxicity and oxidative stress in albino rats. Toxicol Ind Health 28:876–85
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF, Poulos TL. (2013). Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans 42:3116–26
   PubMed Web of Science ®Google Scholar
• Szulawska A, Czyz M. (2006). Molecular mechanisms of anthracyclines action. Postepy Hig Med Dosw (Online) 60:78–100
   PubMedGoogle Scholar
• Tang W, Stearns RA. (2001). Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185–98
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD, Podoll TD, et al. (1994). Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557–66
   PubMed Web of Science ®Google Scholar
• Wang JF, Zhang KC, Chou KC, et al. (2009). Structure of cytochrome p450s and personalized drug. Curr Med Chem 16:232–44
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Ido A, Kurihara T, et al. (2006). Serum aminotransferase activity as a predictor for estimation of total clearance of hepatically metabolized drugs in rats with acute hepatic failure. Biol Pharm Bull 29:141–5
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu R, Xia ZK, et al. (2012). Protective effects of sinomenine against doxorubicin-induced nephrosis in rats. J Asian Nat Prod Res 14:678–87
   PubMed Web of Science ®Google Scholar
• Zhang X, Galinsky RE, Kimura RE, et al. (2010). Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. Drug Metab Dispos 38:61–72
   PubMed Web of Science ®Google Scholar
• Zhanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, Anwar-Mohamed A, Aboutabl ME, et al. (2011). Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos 39:1440–50
   PubMed Web of Science ®Google Scholar